Colon-targeted complement C5a1 receptor inhibition using pH-sensitive nanoparticles ameliorates experimental colitis. - Cui CS; Lerskiatiphanich T; Li XX; Giri R; Liu N; Kumar V; Whittaker AK; Han FY; Clark RJ; Begun J; Lee JD; Woodruff TM (British journal of pharmacology, 2025)